Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference
Satellos to Host Virtual KOL Event on SAT-3247 in Duchenne Muscular Dystrophy
Satellos to Participate in Upcoming Investor Conferences
Satellos Bioscience (NASDAQ:MSLE) is now covered by analysts at
Weiss Ratings. They set a "sell (d-)" rating on the stock.
Satellos Announces First Participant Dosed in Phase 2 Pediatric Study of SAT-3247 for Duchenne Muscular Dystrophy